

Press release

18 January 2013

Vemedia announces successful closing of the public take-over bid by Versailles B.V. as well as the acquisition of Excilor

Information regarding the successfully closed voluntary public take-over bid by Versailles B.V. (November 2012 – January 2013)

Vemedia, the leading and innovative player in OTC (prescription-free medicines), self-care and in-pharmacy compounding, announces that during the squeeze-out bid (which ran until 16 January 2013) 137,532 shares and 464,100 warrants have been tendered. Together with the shares and warrants which were already tendered during the initial acceptance period and the shares acquired by Versailles B.V. under the sales and purchase agreement dated 11 October 2012, this represents 99.73% of the outstanding shares and 100% of the warrants. Payment of the shares and warrants which were tendered during the squeeze-out bid is foreseen on 21 January 2013. The remaining, non-tendered shares will automatically (*de jure*) be transferred to Versailles B.V. with consignment of the necessary funds for the payment of the price to the "*Deposito- en Consignatiekas/la Caisse des Dépôts et de Consignations*". These shareholders remain entitled to the payment of the offer price, but need to contact the *Deposito- en Consignatiekas/la Caisse des Dépôts et de Consignations*" where the corresponding funds will remain available during a period of thirty years. More information regarding the closed public take-over bid can be found under the section News in the press releases dated 16 and 23 November 2012 and under the section Shareholders (where the prospectus is also available) on the website www.vemediapharma.com.

Acquisition of Excilor

In the meantime, Vemedia also acquired the activities of JeCare, the Belgian company which has a leading position in the market of nail fungus treatment with the brand Excilor in Belgium, Italy and the UK.. This acquisition represents an annual turnover of approximately € 10 million and reflects the consolidation potential within the sector, as well as the role of Vemedia within this consolidation movement. This acquisition brings the total number of acquisitions by Vemedia during the past 6 years to 11.

Remko Hilhorst, Partner at UK and advisor of the IK2007 Fund: "*We are delighted to announce the acceptance of shareholders representing 99.7% of the shares of Vemedia. We are looking forward to cooperate with Yvan and his team. With the acquisition of Excilor, we already realised an important acquisition within the footcare segment.*"

Yvan Vindevogel, CEO Vemedia: "*We are delighted with the support given by our shareholders. We are currently already in the process of further implementation of our consolidation strategy, which is an integral part of the rationale for our partnership with IK. We are looking forward to future transactions, together with IK.*"

For questions contact:

IK Investment Partners

Remko Hilhorst, Partner

Tel: +44 20 7304 4300

Charlotte Laveson, Communication

Tel: +44 20 7304 7136

Vemedica

Yvan Vindevogel, CEO

Tel: +32 475 45 33 20

About Vemedica Pharma NV

The Vemedica group, with main presence in the Netherlands, Belgium, Spain, Portugal and Italy, is a leading and innovative player in OTC (prescription-free medicines) self-care and in-pharmacy compounding. The group is active in various European countries and also exports its products beyond Europe. For additional information about the Vemedica group, see www.vemediapharma.com

About IK Investment Partners

IK Investment Partners is a Pan-European private equity firm focused on investments in three regions; the Nordics, Germany/CEE and France Benelux. Since 1989, IK Funds has invested approximately €5.6 billion in over 80 European companies. IK Funds invests with the management of mid-sized companies that have strong improvement potential, operating in the business services, care, industrial goods and consumer goods sectors. The current portfolio comprises 22 companies with total turnover of close to €7.5 billion. For more information visit: www.ikinest.com